Equitoxicity Cisplatin-RONC® and Cisplatin-Teva at a single injection to mice and rats
https://doi.org/10.17650/1726-9784-2018-17-3-65-69
Abstract
Introduction.The development of high-quality domestic reproduced dosage form of сisplatin is necessary to improve the treatment conditions of cancer patients.
Purpose of research.Comparative preclinical study of acute toxicity of newly developed in SIC Oncology reproduced dosage form Cisplatin-RONC® with commercial preparation Cisplatin-Teva.
Materials and methods.The standard methods of estimation of acute toxicity of preparations on small laboratory rodents are used.
Results.Acute toxicity of the compared forms of cisplatin is not significantly different from the effect on the survival and body weight of experimental animals.
Summary.Compared generic and commercial formulations cisplatin almost equitoxic after a single intravenous administration to mice and rats.
About the Authors
V. M. Bukhman
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
N. P. Ermakova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
O. I. Konyaeva
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
N. Yu. Kulbachevskaya
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
A. A. Sergeev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
V. A. Chaley
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
References
1. Apps M.G., Choi E.H., Wheate N.J. The state-of-play and future of platinum drugs. Endocr Relat Cancer 2015;22(4):219–33. DOI:10.1530/ERC-15-0237. PMID: 26113607.
2. Garin A.M., Bazin I.S. Guide to drug therapy solid tumors. Moscow: INFOTECH: LEKRUS, 2015. 529 p. (InRuss.)
3. Reutovich M.Yu., Bychkovsky P.M., Yurkshtovich T.L. et al. Comparative evaluation of the antitumor activity of an aqueous solution of cisplatin and its hydrogel form in an in vivo experiment. Rossiysky Bioterapevtichesky Zhurnal =Russian Journal of Biotherapy 2016;15(1):95–6 (In Russ.)
4. Adler-Moore J.P., Gangneux J.P., Pappas P.G. Comparison between liposomal formulations of amphotericin B Med Mycol 2016;54(3):223–31. DOI:10.1093/mmy/myv111. PMID: 26768369.
5. Niho S., Yamanaka T., Umemura S. et al. Renal toxicity caused by brandname versus generic cisplatin: a comparative analysis. Jpn J Clin Oncol. 2013;43(4):390–5. DOI:10.1093/jjco/hyt020. PMID: 23444114.
6. Sekine I., Kubota K., Tamura Y. et al. Innovator and generic cisplatin formulations: comparison of renal toxicity. CancerSci 2011;102(1):162–5. DOI:10.1111/j.1349-7006.2010.01764.x. PMID: 21054679.
7. Davydov M.I. The appeal of the editor-in-chief. Vestnik RONC im. N.N. Blohina = Journal of N.N. Blokhin Russian cancer research center 2015–2016;26–27(4–1): 3–4 (In Russ.)
Review
For citations:
Bukhman V.M., Ermakova N.P., Konyaeva O.I., Kulbachevskaya N.Yu., Sergeev A.A., Chaley V.A. Equitoxicity Cisplatin-RONC® and Cisplatin-Teva at a single injection to mice and rats. Russian Journal of Biotherapy. 2018;17(3):65-69. (In Russ.) https://doi.org/10.17650/1726-9784-2018-17-3-65-69
Views:
492
Email this article 
